Evaluation the Risk Factors that are Associated with Osteoporosis in Post Kidney Transplantation in a Sample of Iraqi Patients

Angham A. Hasan *,1, Munaf H. Abd alrazak ** and Hassan M. Abbas Al-Temimi ***

* Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq.
** Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq.
*** Ministry of Health and Environment, Baghdad, Iraq.

Abstract

Renal transplantation is a principal treatment option for end-stage kidney failure. Bone loss and fracture are serious complications of kidney transplantation, associated with morbidity and mortality. The pathogenesis of post-transplantation bone loss is multifactorial and complex. There are changes in the normal bone remodeling system which will lead to more accelerated osteoporotic changes compared to normal individuals. The current work aimed to investigate the incidence of osteoporosis in post kidney transplant patients when compared to the general population. And study the relationship between post kidney transplant immunosuppression therapy and osteoporosis and determine some biochemical changes. Also to evaluate the bone mass and the possible correlation between demographic data and the development of osteoporosis. A case control study, conducted in the Kidney Transplant Center – Medical City Complex during the period (from October 2018 till April 2019), seventy-five kidneys transplant patients were participated in the present study including (23 females & 52 males). Apparently healthy seventy-five subjects were selected to participate as a normal group for comparison (control) including (35 females and 40 males). All participants were examined for their bone density using DEXA scan (T – score) and those with cut – point ≤ 2.5 were diagnosed as having osteoporosis (lumbar and hip bones were examined). The prevalence of osteoporosis and osteopenia was significantly higher in transplant patients compared to control for both lumber and hip bones. T- score was significantly lower in the transplant patients compared to control for both lumbar (-1.9±0.8 vs. -1.1±0.7) and hip bones (-2.3±0.9 vs. -1.3±0.8). In logistic regression analysis; only gender and BMI were the predictors of osteoporosis for lumbar bone, while; the BMI and serum calcium were the predictors of osteoporosis for hip bones. In conclusion, Osteoporosis in post-rental transplant patients is high when compared to general population, only corticosteroids significantly increase risk of osteoporosis, biochemical marker serum level in post kidney transplant patients are significantly different when compared with the general population but did not increase risk of osteoporosis and Body mass index is a risk factor for both lumbar and hip bones osteoporosis, while gender and serum calcium are risk factors for osteoporosis in lumbar and hip bones respectively.

Keywords: Osteoporosis, Renal transplant, T – score, Immunosuppressant drugs.

1Corresponding author E-mail: pharmacistangham@yahoo.com
Received: 28/11 / 2019
Accepted: 15 / 2 / 2020
Osteoporosis in post kidney transplantation

Introduction
The primary function of Kidney is to maintain stable internal equilibrium by eliminating excess water, electrolytes, and other byproducts, through the filtration system, or kidney transplant. Transplant result in better outcome in comparison with dialysis (2). However, it has its drawbacks, including low availability of kidney from donors, use of chronic immunosuppressant medications and others factors; these factors together with superior outcome compared to dialysis lead to the development of criteria for selecting candidates for the operation to include as many as possible patients to benefit from transplantation (3).

In order to prevent graft loss that caused by immune reaction, several protocol develop, these protocols will prevent acute rejection. Currently reduction of side effects that caused by these protocols become as important role in reducing the incidence of acute rejection. In the present time, intensive immunosuppression therapy in the early stages of the transplant become as paramount, followed by maintenance protocol to reduce the risk of rejection (4).

However, many of these drugs have side effects that will result in more deterioration of bone density and osteoporosis. Osteoporosis disease that show reduction in bone mass, micro architectural disruption, and enhanced skeletal fragility, with subsequent low bone strength and high rates of fracture (5). After renal transplantation, there are changes in the normal bone remodeling system which will lead to more accelerated osteoporotic changes compared to normal individuals, while for transplantation-related bone loss results from both an increase in the rate of resorption and a decrease in the rate of bone formation (6). The current work aimed to investigate the incidence of osteoporosis in post kidney transplant patients when compared to the general population, and study the relationship between post kidney transplant immunosuppression therapy and osteoporosis and determine some biochemical changes. Also to evaluate the bone mass by using dual X-ray absorptiometry (DEXA) and the possible correlation between demographic data and the development of osteoporosis.

Subjects and Method

Study design
A case control study applied in Kidney Transplant Center – Medical City Complex during the period from October 2018 till April 2019.

Patients and controlled subjects
Seventy-five kidney transplant patients were participated in the present study including (23 females & 52 males). The age range was (15 - 65) years. Apparently seventy-five healthy subjects were selected to participate as a normal group for comparison (control) including (35 females & 40 males). The age range of these subjects was (15 - 65). The follow up of kidney transplant patients was made by specialist's surgeon.

Inclusion criteria
1.  Patient age range (15 -65) years.
2.  More than 6 months’ post kidney transplant operation

Exclusion criteria
1.  Endocrine diseases.
2.  Infectious diseases.
3.  Gastrointestinal diseases.
4.  Lung disease.
5.  Patients using drug that effect calcium level.
**Bone density assessment**

DEXA scan was used for the assessment of bone density, with T-score ≤ -2.5 to define osteoporosis and between -1.0 to -2.5 to define osteopenia. (7)

**Laboratory procedure**

A 5 ml venous blood sample from each participant was collected and then sent for laboratory analysis in the Medical City Complex campus, serum (calcium, phosphorous (PO4), alkaline phosphatase (ALP), vitamin D3, parathyroid hormone (PTH), and albumin) measurement were recorded.

**Statistical analysis**

For the assessment of continuous variables, independent t-test was used, while for categorical variables chi square test used, ordinal logistic regression analysis used to examine the risk of osteoporosis (in which the order of category from lowest to highest was normal bone, osteopenia, and osteoporosis). All analysis carried out using SPSS version 22.0.0 (Chicago, IL) and GraphPad Prism version 8.2 (San Diego, California USA). p value considered when appropriate to be significant if less than 0.05

**Results**

The study included 150 participants, mean age of patients was not significantly different in the study group compared to control (40.9±12.2 vs. 38.4±11.5 years, respectively), with age range from 15 – 65 years, the commonest age group for both study and control group was between 40 – 49 years (26.7% vs. 28.0%, respectively). BMI was significantly lower in the study group compared to control (25.2±3.8 vs. 27.0±7.5 kg/m², respectively). There was no significant difference in gender between study and control groups, male to female ratio (2.26:1 vs. 1.14:1, respectively), as illustrated in table 1.

**Table 1. Assessment of demographic, clinical, and laboratory data.**

| Variables                    | Control      | Study        | p-value |
|------------------------------|--------------|--------------|---------|
| Number                       | 75           | 75           | -       |
| Age (years), mean ± SD       | 38.4±11.5    | 40.9±12.2    | 0.191 * |
| BMI (kg/m²), mean ± SD       | 27.0±7.5     | 25.2±3.8     | 0.068 # |
| Gender, n (%)                |              |              | 0.065 # |
| Female                       | 35 (46.7%)   | 23 (30.7%)   |         |
| Male                         | 40 (53.3%)   | 52 (69.3%)   |         |
| Transplant duration (years), | -            | 4.0 (2.0 – 7.0) | -       |
| Treatment, n (%)             | -            | -            | -       |
| MMF                          | -            | 74 (98.7%)   | -       |
| Cyclosporine                 | -            | 26 (34.7%)   | -       |
| Sirolimus                    | -            | 7 (9.3%)     | -       |
| Tacrolimus                   | -            | 38 (50.7%)   | -       |
| S.Ca (mg/dl), mean ± SD      | 9.0±0.4      | 9.5±0.7      | <0.001 *|
| S.Po4 (mg/dl), mean ± SD     | 4.1±0.6      | 3.3±0.6      | <0.001 *|
| S.ALPl(U/L), mean ± SD       | 65.6±17.7    | 101.2±35.8   | <0.001 #|
| S.VitaminD3s (ng/ml), mean ± SD | 22.5±15.0 | 22.9±13.4   | 0.871 * |
| S.PTH(Pg/ml), mean ± SD      | 39.4±22.8    | 82.6±66.9    | <0.001 #|
| S. Albumin(mg/d), mean ± SD  | 3.8±0.6      | 3.6±0.3      | 0.002 * |

* Significant difference indicates p-value <0.05, compared to control
* Non-significant difference indicates p-value ≥0.05
MMF: Mycophenolate mofetil
S.ALP: Serum Alkaline phosphatase, S.Ca: Serum calcium, S.PTH: Serum parathyroid hormone, S.PO4: Serum phosphorus.

The prevalence of osteoporosis and osteopenia was significantly higher in transplant patients compared to control for bone lumbar and hip bones (Figure 1 and 2), also, T-Score was significantly lower in the transplant patients compared to control for both lumbar and hip bones - as illustrated in table 2.
Table 2. Assessment of bone status.

| Variables         | Control | Study | p-value |
|-------------------|---------|-------|---------|
| Number            | 75      | 75    | -       |
| T – score, mean ± SD |        |       |         |
| Spine bone        | -1.1±0.7| -1.9±0.8| <0.001 |
| Hip bone          | -1.3±0.8| -2.3±0.9| <0.001 |
| Lumbar bone, n (%)|         |       | <0.001 |
| Normal            | 39 (52.0%)| 14 (18.7%)|         |
| Osteopenia        | 34 (45.3%)| 36 (48.0%)|         |
| Osteoporosis      | 2 (2.7%) | 25 (33.3%)|         |
| Hip bone, n (%)   |         |       | <0.001 |
| Normal            | 43 (57.3%)| 7 (9.3%) |         |
| Osteopenia        | 21 (28.0%)| 23 (30.7%)|         |
| Osteoporosis      | 11 (14.7%)| 45 (60.0%)|         |

Figure 1. Osteoporosis status for spinal (lumbar) bones. *** Highly significant difference (p-value < 0.001). **** Very highly significant difference (p-value < 0.0001)

Only gender and BMI were the predictors of osteoporosis for lumbar bone, as illustrated in Table 3, while The BMI and serum calcium were the predictors of osteoporosis for hip bone, as illustrated in table 4.

Table 3. Ordinal regression analysis of the predictor of osteoporosis for lumbar bone in the study group

|                | β     | OR   | 95%CI  | p-value |
|----------------|-------|------|--------|---------|
| Age            | 0.020 | 1.020| 0.984-1.057| 0.284   |
| Gender (female)| -1.107| 3.026| 1.118-8.188| 0.029*  |
| BMI            | 0.163 | 0.850| 0.748-0.966| 0.013*  |
| Transplant duration | 0.047 | 1.048| 0.961-1.143| 0.286   |
| MMF            | -     | -    | -      | -       |
| Cyclosporine   | 0.252 | 1.286| 0.516-3.208| 0.589   |
| Sirolimus      | 0.035 | 1.036| 0.249-4.317| 0.961   |
| Tacrolimus     | -0.162| 0.850| 0.362-2.0 | 0.710   |
| S.PO4          | 0.141 | 1.151| 0.562-2.358| 0.700   |
| S.ALP          | -0.003| 0.997| 0.986-1.008| 0.591   |
| S.Vitamin D3   | 0.011 | 1.011| 0.977-1.047| 0.522   |
| S.PTH          | 0.001 | 1.001| 0.995-1.008| 0.644   |
| S.Albumin      | -0.023| 0.977| 0.275-3.475| 0.971   |
| S.Calcium      | -0.315| 0.730| 0.379-1.406| 0.346   |

β: Ordinal logistic regression analysis, OR: odd ratio, CI: confidence interval. It cannot be calculated for MMF
*Significant relationship between variables (p-value<0.05)
In the present study, mean age ±SD of transplant patients were 40.9 ± 12.2 years, with 73.3% of them distributed between 30 – 59 years, this result is close to Coco et al; study which included 59 kidney transplant patients with mean age of 45.5 ± 13 years (10), also in agreement with Walsh et al; study which included 93 transplant patients with mean age±SD for treatment was (46.1 ± 12.77 years) and for control (46.1 ± 12.93 years) (11). In this study patients were younger than patients included in the Smerud et al; study with mean age 51.4 ± 13.8 years for all the 129 transplant patients (12), also lower than other study with mean age of 50.7 ± 15.5 years for 49 control transplant patients (13).

In the present study, mean T – score for lumbar-1.9±0.8 while for hip bone it was -2.3±0.9 in study group. In Marcén et al study, for the lumbar bones (L2-L4) T-score, - 1.88±0.99, and for femoral neck was - 1.52±0.88, which is close to present findings (14). In Mazzaferro study, T – score was -1.290 ± 1.286 which higher than current study (15). In Durieux et al study, T – score was – 2 ± 1.3 at the lumbar spine and - 1.9 ± 1.2 at the femoral neck which is close to current study (16).

In the current study, the prevalence of osteoporosis, osteopenia, and normal bone for spinal bone were 33.3%, 48.0% , and 18.7% ;while for hip bone it was 60.0% ,30.7% ,and 9.3% .

In Gregorini et al, a retrospective cohort study, 60.3% of the patients had normal bone, while osteopenia and osteoporosis were present in 24.6% and 15.1%, respectively (17), which is in disagreement with the current study since osteoporosis in the current study is higher. In Marcén et al study, 20% had normal BMD in the lumbar spine; 52.5% had osteopenia and 27.5% had osteoporosis. While for femoral neck, 35.0% had normal BMD; 50.0% had osteopenia; and 15.0%, osteoporosis (which mean lower osteoporosis rate when compared to the present result) (12). In Durieux et al; studyis agree with current study for the lumbar spine 37% had osteoporosis, and 44% had osteopenia, but disagree for the femoral neck 37% had osteoporosis and 40% had osteopenia (16). In Marcen et al study, 41.9% had osteopenia and 14% had osteoporosis (18).

The high rate of osteoporosis that observed in this study can be explained by the long duration of transplantation that can will more progressive bone disease, also all patient received corticosteroids (CS) and for extended period of time, since CS is known to cause bone loss by its inhibitory effect on osteoblast cells, and activation of osteoclastic activity, reduction of Ca absorption from the GIT, enhance renal Ca excretion, and increased section of PTH (19).

In the present study, 34.7% of the patients received cyclosporine(CSA) (as part of combination therapy), also there is no significant relationship between CyA with osteoporosis, (with OR, 95%CI = 1.286 ,0.516-3.208; for lumbar bone and = 1.321 ,
0.511–3.419 for hip bones), which is in agreement with Martín-Fernández (20). This can be explained by the lack of effect of CsA on bone, or since the decrease in BMD in transplant recipients is difficult to evaluate because CsA is usually administered together with glucocorticoids (20).

Tacrolimus was received in the present study by 50.7% patients (as part of combination therapy), also there was no significant relationship between tacrolimus and osteoporosis, (with OR, 95%CI = 0.850, 0.362–2.0; for lumbar bone and, OR, 95%CI = 1.023, 0.414–2.527; for hip bones). FK506-based regimens may benefit the skeleton by lowering steroid exposure in transplant recipients. In a small group of kidney-transplant recipients followed for 1 year, Goffin et al. (21), noted that those who received tacrolimus had a small net increase in bone density compared to a loss observed in those who received cyclosporine.

Sirolimus might impair bone formation by interfering with the proliferation and differentiation of osteoblasts and might contribute to the impairment of osteoclast-mediated bone resorption (20). In the present study, only 9.3% of patients received sirolimus, there was no correlation between the use of sirolimus and osteoporosis (with OR, 95%CI = 1.036, 249–4.317; for lumbar bone and, OR, 95%CI = 0.524, 0.998–2.807; for hip bones), it is a more novel immunosuppressive agent that produces lower effects on bone (22).

In the current study, 98.7% of patients received mycophenolatemofetil (MMF) (as a part of combination therapy), and there was no significant relationship between (MMF) and osteoporosis. Mycophenolatemofetil has no influence on bone formation and mass in clinical observations (23).

Also, the logistic regression analysis revealed that the BMI (OR, 95%CI = 0.850, 0.748–0.966) and gender (OR, 95%CI = 3.026, 1.118–8.188) were risk factors that are associated with osteoporosis risk for lumbar bone. While for hip bone, logistic regression analysis for BMI (OR, 95%CI = 0.870, 0.760–0.996), and serum calcium (OR, 95%CI = 0.514, 0.265–0.997) were risk factors that are associated with osteoporosis in hip bone. These results study disagree with the results of another study, where no significant relationship was observed between osteoporosis and gender and body mass index (24). Also differs from another study, where no significant relationship was observed between osteoporosis and serum levels of calcium (25) but it agrees with the same study, regarding non-significant relationship between osteoporosis and serum phosphorous and serum parathyroid hormone level.

Osteoporosis after kidney transplantation is multifactorial, while pathophysiologic mechanisms responsible for this condition is not completely elucidated. Pre-transplantation risk factors include duration of dialysis, high or low parathyroid hormone (PTH) levels and preexisting bone disease. Post-transplantation risk factors associated with bone loss and/or fractures are deceased kidney donor, immunosuppressive regimen choice (glucocorticoids, calcineurin inhibitors), and time since transplantation, hypophosphatemia and graft dysfunction. Additional risk factors such as postmenopausal status for women and presence of diabetes have been considered as possible culprits, in conjunction to the classical osteoporosis risk factors such as age and female gender (26).

Conclusion

Osteoporosis in post-renal transplant patients is high when compared to general population, T-score was significantly lower in the transplant patients when compared to control for both lumbar and hip bone, immunosuppressant therapy (mycophenolate mofetile, tacrolimus, cyclosporine and sirolimus) did not increase the risk of osteoporosis, but corticosteroids significantly increase risk of osteoporosis, Biochemical marker serum level in post kidney transplant patients are significantly different when compared with general population but did not increase risk of osteoporosis. Body mass index is a risk factor for both lumbar and hip bones osteoporosis, while gender and serum calcium are risk factors for osteoporosis in lumbar and hip; respectively.

Conflict of Interest

There are no conflicts of interest.

References

1. Bailey MA, Shirley DG, Unwin RJ. Renal Physiology. In: Johnson RJ, Feehally J, Floege J. Comprehensive clinical nephrology. 5th ed. Philadelphia: Elsevier Saunders; 2015. p. 14–27.

2. Gabriel CO, Helen B, and John L.R.. Impact of Cadaveric Renal Transplantation on Survival in Patients Listed for Transplantation. J Am SocNephrol .2005; 16 (6) 1859-1865.

3. Fritsche L, Vanrenterghem Y, Nordinal KP, Grinyo JM, Moreso F, Budde K, et al. Practice variations in the evaluation of adult candidates for cadaveric kidney transplantation: a survey of the European Transplant Centers. Transplantation. 2000;70(10):1492-7.

4. Wiseman AC, Cooper JE. Prophylaxis and Treatment of Kidney Transplant Rejection. In: Johnson RJ, Feehally J, Floege J, editors. Comprehensive clinical nephrology, 5 th ed. Philadelphia: Elsevier Saunders; 2015. p. 1176-87.

5. Anne K, Lucile A, Tamsen B, Steven N. B, Scott D. B, David R. G. NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA.2001; 285: 785–95.

6
6. Stein E, Shane EP. Osteoporosis in Organ Transplant Patients. In: Marcus R, Feldman D, Dempster DW, Luckey M, Cauley JA. Osteoporosis (4th ed). San Diego: Academic Press; 2013. p. 1349-74.
7. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002; 288: 1889–97.
8. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. The Lancet 2011;377(9773):1276-87.
9. Lindsay R, Silverman S, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. J Am Med Ass 2001; 285: 320–323
10. Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, et al. Prevention of Bone Loss in Renal Transplant Recipients: A Prospective, Randomized Trial of Intravenous Pamidronate. Journal of the American Society of Nephrology 2003;14(10):2669-76.
11. Walsh SB, Altmann P, Pattison J, Wilkie M, Yaqoob MM, Dudley C, et al. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. American journal of kidney diseases 2009;53(5):856-65.
12. Smerud KT, Dolgos S, Olsen IC, Asberg A, Sagedal S, Reisaeter AV, et al. A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation. American journal of transplantation 2012;12(12):3316-25.
13. Torregrosa JV, Fuster D, Gentil MA, Marcen R, Guirado L, Zarraga S, et al. Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients. Transplantation 2010;89(12):1476-81.
14. Marcén R, Caballero C, Uriol O, Fernández A, Villafruela JJ, Pascual J, et al. Prevalence of Osteoporosis, Osteopenia, and Vertebral Fractures in Long-Term Renal Transplant Recipients. Transplantation proceedings 2007;39(7):2256-8.
15. Mazzaferrro S, Diacinti D, Proietti E, Barresi G, Baldinelli M, Pisani D, et al. Morphometric X-ray absorptiometry in the assessment of vertebral fractures in renal transplant patients. Nephrology, dialysis, transplantation 2006;21(2):466-71.
16. Durieux S, Mercadal L, Orec P, Dao H, Rioux C, Bernard M, et al. Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation 2002;74(4):496-500.
17. Gregorini M, Sileno G, Pattonieri EF, Corradetti V, Abelli M, Ticozzelli E, et al. Understanding Bone Damage After Kidney Transplantation: A Retrospective Mono-centric Cross-Sectional Analysis. Transplantation proceedings 2017;49(4):650-7.
18. Marcen R, Caballero C, Pascual J, Teruel JL, Tenorio M, Ocani J, et al. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. Transplantation 2006;81(6):826-31.
19. Rubin MR, Bilezikian JP: Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: A re-examination of the evidence. J Clin Endocrinol Metab 2002: 87: 4033–4041
20. Martin-Fernandez M, Rubert M, Montero M, de la Piedra C. Effects of Cyclosporine, Tacrolimus, and Rapamycin on Osteoblasts. Transplantation proceedings 2017;49(9):2219-24.
21. Goffin E, Devogelaer J-P, Lalaoui A, et al: Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl Int 2002;15:73-80.
22. Campistol JM, Holt DW, Epstein S. Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. Transpl Int. 2005; 18:1028-35.
23. Lei S, Xu-Biao X, Long-K. P, Shao-J. Y, Ya-T. P. Mechanism and Treatment Strategy of Osteoporosis after Transplantation. International Journal of Endocrinology 2015; p 10.
24. Ahmadpoor P, Reisi S, Makhdoomi K, Ghafari A, Sepehrvand N, Rahimi E. Osteoporosis and related risk factors in renal transplant recipients. Transpl Proc 2009;41:2820–2822.
25. Esra O. H, Hussein Y. S. Prevalence and risk factors of osteoporosis in kidney transplant recipients: Dual-Energy x-ray absorptiometry scan study. Medical Journal of Babylon. 2018; 15: 267-270.
26. Evangelia D, Konstantinos L, Theodoros E, Vassiliou L. Osteoporosis after renal transplantation. International Urology and Nephrology. 2015;47:503–511.